EP0885205A4 - Antagonistes des recepteurs de fibrinogenes - Google Patents

Antagonistes des recepteurs de fibrinogenes

Info

Publication number
EP0885205A4
EP0885205A4 EP97906712A EP97906712A EP0885205A4 EP 0885205 A4 EP0885205 A4 EP 0885205A4 EP 97906712 A EP97906712 A EP 97906712A EP 97906712 A EP97906712 A EP 97906712A EP 0885205 A4 EP0885205 A4 EP 0885205A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
fibrinogen receptor
fibrinogen
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97906712A
Other languages
German (de)
English (en)
Other versions
EP0885205A1 (fr
Inventor
John Wai
Mark E Duggan
Thorsten E Fisher
George D Hartman
James J Perkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606489.4A external-priority patent/GB9606489D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0885205A1 publication Critical patent/EP0885205A1/fr
Publication of EP0885205A4 publication Critical patent/EP0885205A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97906712A 1996-02-28 1997-02-24 Antagonistes des recepteurs de fibrinogenes Withdrawn EP0885205A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1238096P 1996-02-28 1996-02-28
US12380P 1996-02-28
GBGB9606489.4A GB9606489D0 (en) 1996-03-27 1996-03-27 Fibrinogen receptor antagonists
GB9606489 1996-03-27
PCT/US1997/002712 WO1997031910A1 (fr) 1996-02-28 1997-02-24 Antagonistes des recepteurs de fibrinogenes

Publications (2)

Publication Number Publication Date
EP0885205A1 EP0885205A1 (fr) 1998-12-23
EP0885205A4 true EP0885205A4 (fr) 2002-11-27

Family

ID=26309005

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97906712A Withdrawn EP0885205A4 (fr) 1996-02-28 1997-02-24 Antagonistes des recepteurs de fibrinogenes

Country Status (5)

Country Link
EP (1) EP0885205A4 (fr)
JP (1) JP2000505471A (fr)
AU (1) AU712082B2 (fr)
CA (1) CA2246756A1 (fr)
WO (1) WO1997031910A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU721130B2 (en) * 1996-06-28 2000-06-22 Merck & Co., Inc. Fibrinogen receptor antagonists
US6586617B1 (en) * 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
JP2001026506A (ja) * 1999-04-28 2001-01-30 Takeda Chem Ind Ltd スルホンアミド誘導体
US6617343B1 (en) 1999-08-27 2003-09-09 Eli Lilly And Company Hypoglycemic N,N-arylsulfonylglycine compounds
HUP0400651A2 (hu) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
US6906192B2 (en) 2000-11-07 2005-06-14 Bristol Myers Squibb Company Processes for the preparation of acid derivatives useful as serine protease inhibitors
WO2002037937A2 (fr) 2000-11-07 2002-05-16 Bristol-Myers Squibb Company Derives d'acides utilises comme inhibiteurs de la serine protease
WO2002102780A1 (fr) * 2001-06-18 2002-12-27 Ono Pharmaceutical Co., Ltd. Compose derive de tetrahydroquinoline et medicament contenant ledit compose comme principe actif
WO2005049589A2 (fr) * 2003-10-14 2005-06-02 Cadila Healthcare Limited Nouveaux composes heterocycliques
GB0421908D0 (en) 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
CA2613235A1 (fr) * 2005-06-30 2007-01-11 Prosidion Limited Agonistes de gpcr
CN101827826A (zh) 2007-10-16 2010-09-08 诺瓦提斯公司 4-苯基-5-氧代-咪唑衍生物、其药物组合物及其应用
JP5501251B2 (ja) 2008-01-11 2014-05-21 アルバニー モレキュラー リサーチ， インコーポレイテッド Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 d’azabicycloalcane-indole et d’azabicycloalcane-pyrrolo-pyridine, procédés de préparation, et utilisation de ceux-ci
WO2011003012A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 azapolycycles substitués par azinone, leurs procédés de fabrication et leur utilisation
EP2448585B1 (fr) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Antagonistes de mch-1 d azépino[b]indole et pyrido-pyrrolo-azépine azinone-substitué, procédés de préparation, et utilisation de ceux-ci
WO2011027888A1 (fr) * 2009-09-07 2011-03-10 大日本住友製薬株式会社 Dérivé diamide-phényle et son sel pharmaceutiquement acceptable
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
RU2681849C2 (ru) 2013-06-05 2019-03-13 Си энд Си РИСЕРЧ ЛЭБОРЕТРИЗ Гетероциклические производные и их применение
MY187540A (en) 2014-08-01 2021-09-28 Nuevolution As Compounds active towards bromodomains
SG11202007646UA (en) 2018-02-13 2020-09-29 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
TWI732245B (zh) 2018-07-13 2021-07-01 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0034284A2 (fr) * 1980-02-18 1981-08-26 Tanabe Seiyaku Co., Ltd. Dérivé de pipérazine, procédés pour sa préparation et compositions thérapeutiques le contenant
DE3622865A1 (de) * 1986-07-08 1988-01-21 Bayer Ag N-phenyl-substituierte glycine
EP0478328A1 (fr) * 1990-09-27 1992-04-01 Merck & Co. Inc. Antagonistes de récepteur du fibrinogène
EP0478363A2 (fr) * 1990-09-27 1992-04-01 Merck & Co. Inc. Nouveaux sulfonamides comme antagonistes des récepteurs fibrinogéniques
JPH04182481A (ja) * 1990-11-19 1992-06-30 Nisshin Flour Milling Co Ltd ロダニン誘導体
US5183810A (en) * 1990-02-13 1993-02-02 Merck & Co., Inc. Imidazole angiotensin II antagonists incorporating a substituted benzyl element
GB2271567A (en) * 1992-10-14 1994-04-20 Merck & Co Inc Fibrinogen receptor antagonists
WO1994012181A1 (fr) * 1992-12-01 1994-06-09 Merck & Co., Inc. Antagonistes des recepteurs du fibrinogene
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
EP0718287A2 (fr) * 1994-12-23 1996-06-26 Dr. Karl Thomae GmbH Dérivés de pipérazine, médicaments les contenant, leur application, et procédés pour leur préparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
AU666577B2 (en) * 1992-08-19 1996-02-15 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulator
ATE202345T1 (de) * 1993-03-29 2001-07-15 Astrazeneca Ab Heterozyklische derivate als plätchenaggregationsinhibitoren

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0034284A2 (fr) * 1980-02-18 1981-08-26 Tanabe Seiyaku Co., Ltd. Dérivé de pipérazine, procédés pour sa préparation et compositions thérapeutiques le contenant
DE3622865A1 (de) * 1986-07-08 1988-01-21 Bayer Ag N-phenyl-substituierte glycine
US5183810A (en) * 1990-02-13 1993-02-02 Merck & Co., Inc. Imidazole angiotensin II antagonists incorporating a substituted benzyl element
EP0478328A1 (fr) * 1990-09-27 1992-04-01 Merck & Co. Inc. Antagonistes de récepteur du fibrinogène
EP0478363A2 (fr) * 1990-09-27 1992-04-01 Merck & Co. Inc. Nouveaux sulfonamides comme antagonistes des récepteurs fibrinogéniques
JPH04182481A (ja) * 1990-11-19 1992-06-30 Nisshin Flour Milling Co Ltd ロダニン誘導体
GB2271567A (en) * 1992-10-14 1994-04-20 Merck & Co Inc Fibrinogen receptor antagonists
WO1994012181A1 (fr) * 1992-12-01 1994-06-09 Merck & Co., Inc. Antagonistes des recepteurs du fibrinogene
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
EP0718287A2 (fr) * 1994-12-23 1996-06-26 Dr. Karl Thomae GmbH Dérivés de pipérazine, médicaments les contenant, leur application, et procédés pour leur préparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199232, Derwent World Patents Index; Class B02, AN 1992-265155, XP002212437 *
See also references of WO9731910A1 *

Also Published As

Publication number Publication date
EP0885205A1 (fr) 1998-12-23
AU2133297A (en) 1997-09-16
AU712082B2 (en) 1999-10-28
JP2000505471A (ja) 2000-05-09
CA2246756A1 (fr) 1997-09-04
WO1997031910A1 (fr) 1997-09-04

Similar Documents

Publication Publication Date Title
EP0912175A4 (fr) Antagonistes du recepteur de fibrinogene
EP0885205A4 (fr) Antagonistes des recepteurs de fibrinogenes
EP0810994A4 (fr) Antagonistes des recepteurs de fibrinogene
HU9603525D0 (en) Vironectin receptor antagonists
GB9405317D0 (en) Fibrinogen receptor antagonists
EP0866705A4 (fr) Antagonistes du recepteur de fibrinogene
CY2576B1 (en) Vitronectin receptor antagonists
EP0885213A4 (fr) Antagonistes du recepteur du fibrinogene
GB9625843D0 (en) Phenyl spiroethercycloalkyl tachykinn receptor antagonists
EP0796098A4 (fr) Antagonistes des recepteurs du fibrinogene
EP0880511A4 (fr) Antagonistes du recepteur integrine
IL135797A0 (en) Thrombin receptor antagonists
EP0801650A4 (fr) Antagonistes des recepteurs du fibrinogene
HU9502028D0 (en) Fibrinogen receptor antagonists
EP0794779A4 (fr) Antagonistes des recepteurs du fibrinogene
GB9320799D0 (en) Fibrinogen receptor antagonists
GB9515852D0 (en) Fibrinogen receptor antagonists
EP0912182A4 (fr) Promedicaments antagonistes du recepteur de fibrinogene
GB9600344D0 (en) Benzimidzolyl neuropeptide y receptor antagonists
HRP960237A2 (en) Improved isoxazoline fibrinogen receptor antagonists
EP0800395A4 (fr) Antagonistes des recepteurs du fibrinogene
EP0781133A4 (fr) Antagonistes du recepteur de fibrinogene
GB9516643D0 (en) Fibrinogen receptor antagonists
EP0957908A4 (fr) Antagonistes de recepteurs du fibrinogene
GB9708766D0 (en) Fibrinogen receptor antagonist

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 295/155 A, 7C 07D 401/04 B, 7C 07D 401/06 B, 7C 07D 401/12 B, 7C 07D 409/12 B, 7A 61K 31/47 B, 7A 61K 31/445 B, 7A 61K 31/495 B, 7A 61K 31/505 B, 7A 61K 31/725 B, 7C 07D 209/08 B, 7C 07D 471/04 B, 7C 07D 211/22 B, 7C 07D 213/81 B, 7C 07D 211/34 B, 7C 07D 213/82 B, 7C 07D 215/38 B, 7C 07D 295/12 B, 7C 07D 295/14 B, 7C 07D 333/34 B, 7C 07D 333/38 B

A4 Supplementary search report drawn up and despatched

Effective date: 20021011

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020901

R18D Application deemed to be withdrawn (corrected)

Effective date: 20020903